Two strategic investors agreed to invest $2.5 million in MangoRx IP Holdings
Two strategic investors agreed to invest an aggregate $2.5 million in MangoRx IP Holdings, LLC, a subsidiary of Mangoceuticals, Inc., in exchange for membership interests sec.gov. Mangoceuticals announced on October 1, 2026 that the subsidiary had received the first tranche of $1.75 million, and that the investment was made at the subsidiary level with no shares of the parent's common stock issued sec.gov.
Deal facts. Buyer: MANGOCEUTICALS, INC., a listed company in health services. What was bought: named in the filing. Signed: see the filing. Consideration: not stated in the filing. Financing: not stated in the filing. Lender or agent: not named in the filing. Conditions: The initial tranche consists of the equivalent of a 17.5% membership interest on a post-acquisition basis for $1.75 million, and the second tranche consists of the remaining 7.5% membership interest for $750,000, payable within 60 days following the initial closing, or by November 28, 2026, subject to the terms and conditions of the applicable subscription agreement.
The release states the investment in two parts. The first tranche is a 17.5% membership interest on a post-acquisition basis for $1.75 million, and the second tranche is the remaining 7.5% membership interest for $750,000, payable within 60 days following the initial closing, or by November 28, 2026. The filing does not state how the investors financed the purchase, and it names no lender or agent.
Mangoceuticals said the investment provides capital to advance commercialization of the company's antiviral intellectual property portfolio, and that the capital was raised at the subsidiary level with no issuance of shares of the parent's common stock, warrants or other securities.
For context. U.S. jobs in administrative, support and waste management services stood at 9,018.6 thousand in September 2026, according to the Bureau of Labor Statistics (Current Employment Statistics). That is down 15.3 thousand jobs from August 2026 and up 48.5 thousand jobs from September 2025.
An owner of a similar services company can read this structure as investors paying for a business whose value sits in its intellectual property and its telemedicine platform, not in physical assets. Mangoceuticals sells health and wellness products through a secure telemedicine platform under the MangoRx and PeachesRx brands, and the subsidiary that took the investment, MangoRx IP Holdings, holds the antiviral intellectual property the capital is meant to commercialize. The two strategic investors bought membership interests in that subsidiary, which keeps the capital pointed at the IP and the platform where software is taking on more of the work customers pay for. That is the shape of a deal where the asset being funded is the data and the software, and the investors are paying to advance it.
What to watch next is the second tranche. The remaining 7.5% membership interest for $750,000 is payable within 60 days following the initial closing, or by November 28, 2026, so whether that tranche closes on time is the next checkable step. The release also points to the commercialization of the antiviral intellectual property portfolio as the use of the capital, so any later report on how that commercialization advances is what to watch.